Patients Worldwide

RADIESSE^® has been used to treat patients in more than 57 countries, with more than 15 million syringes sold worldwide.

RADIESSE^® provides both immediate and long-term regeneration:

Immediate smoothing wrinkles and folds^1,2*
Long-term biostimulatory effect of revitalizes the
5 key components of the extracellular matrix (ECM)^3-8

Individual results may vary.

Radiesse^® 1.5 cc Syringe

Get Results With Less Product

In two separate clinical studies comparing RADIESSE^® to other leading injectable dermal fillers, overall, patients required less RADIESSE^® to achieve full correction in comparison.^1,2

33% less RADIESSE^® was required for full correction, versus* JUVÉDERM^® Injectable Gel⁹
30% less RADIESSE^® was required for full correction, versus* RESTYLANE^® Injectable Gel¹⁰

Less RADIESSE^® may be required for full correction, giving your practice and your patients more value with each syringe.

*All mention of discontinued products have been removed from this study.

Total Mean Treatment Volume (cc)¹

Chart showing the total mean treatment volume (cc) of Radiesse vs. competitors — Restylane formally known as Perlane at the time of study.
Trademarks other than RADIESSE^® and RADIESSE^® (+) are the property of their respective owners.

Become a provider

RADIESSE^® and RADIESSE^® (+) are indicated for subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, and for the rejuvenation of the hand. RADIESSE^® injectable implant diluted 1:2 with 0.9% sterile saline for injections is intended for the treatment of moderate and severe décolleté wrinkles.

Warnings:

As with all dermal fillers, introduction of RADIESSE^® or RADIESSE^® (+) injectable implant into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction.
Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage, leading to stroke, skin necrosis, and damage to underlying facial structures.
Immediately stop the injection if a patient exhibits any of the following symptoms, including changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure.
Patients should receive prompt medical attention and possibly evaluation by an appropriate healthcare practitioner specialist should an intravascular injection occur.
Use of RADIESSE^® or RADIESSE^® (+) injectable implant in any person with active skin inflammation or infection in or near the treatment area should be deferred until the inflammatory or infectious process has been controlled.
Injection procedure reactions have been observed consisting mainly of short-term (i.e., <7 days) bruising, redness, swelling, lumpiness, pain, itching, discolouration, and tenderness.
Do not overcorrect (overfill) a contour deficiency because the depression should gradually improve within several weeks as the treatment effect of RADIESSE^® (+) injectable implant occurs. In extreme cases site rupture could occur with overcorrection.
Not intended for use in the breasts or for use in the lips.

Consult the Instructions for Use for a complete list of warnings, precautions, and other important safety information. The Instructions for Use are available by calling us at 1-866-815-8715 or found here.

RADIESSE® Instructions for Use. Merz North America, Inc. July 2025.
RADIESSE® (+) Instructions for Use. Merz North America, Inc. April 2023.
Aguilera SB, et al. Aesthet Surg J. 2023;43(10):1063-1090.
Yutskovskaya YA, et al. J Drugs Dermatol. 2017;16(1):68-74.
González N, Goldberg D. J Dermatol Surg. 2019;45(4):547-551.
Yutskovskaya YA, et al. J Drugs Dermatol. 2014;13(9):1047-1052.
Yutskovskaya YA, et al. J Drugs Dermatol. 2020;19(4):405-411.
Nowag B, et al. Presented at: AMWC 2019; Monte Carlo, Monaco; April 2-4, 2019.
Moers-Carpi M, et al. Dermatol Surg. 2007;33(suppl 2):S144-S151.
Moers-Carpi MM, Tufet JO. Dermatol Surg. 2008;34(2):210-215.

Get Results With Less Product

Total Mean Treatment Volume (cc)1

Become a provider

Total Mean Treatment Volume (cc)¹